Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 15, Pages 3821
Publisher
MDPI AG
Online
2019-08-05
DOI
10.3390/ijms20153821
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
- (2019) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
- (2019) Jong Woo Lee et al. Journal of Thoracic Oncology
- Trans ‐3,5,4´‐trimethoxystilbene reduced gefitinib resistance in NSCLC s via suppressing MAPK /Akt/Bcl‐2 pathway by upregulation of miR‐345 and miR‐498
- (2019) Min Lu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
- (2019) Alessandro Russo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: implications for combination therapies
- (2019) Yijun Jia et al. INTERNATIONAL JOURNAL OF CANCER
- A brief review: some compounds targeting YAP against malignancies
- (2019) Zhenxue Tang et al. Future Oncology
- Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
- (2019) Fabio Perrotta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
- (2019) Chih‐Hsi Scott Kuo et al. Thoracic Cancer
- Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model
- (2019) Ping‑Chih Hsu et al. ONCOLOGY REPORTS
- The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1
- (2018) Helena J. Janse van Rensburg et al. CANCER RESEARCH
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model
- (2018) Ping-Chih Hsu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma
- (2018) Ping-Chih Hsu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The rocky road to personalized medicine in acute myeloid leukaemia
- (2018) Bryan Brinda et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer
- (2018) Dongfang Tang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
- (2018) Ross A. Soo et al. LUNG CANCER
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway
- (2018) Dan Jin et al. ONCOLOGY REPORTS
- YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity
- (2018) Xuhao Ni et al. Cancer Discovery
- Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
- (2018) Ting-Fang Lee et al. Scientific Reports
- Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial
- (2018) Lu Yang et al. Thoracic Cancer
- Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors
- (2018) Zhansheng Jiang et al. Thoracic Cancer
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- The Hippo Pathway: Immunity and Cancer
- (2018) Zaid Taha et al. Cancers
- YAP‐TEAD signaling promotes basal cell carcinoma development via a c‐JUN/AP1 axis
- (2018) Dejan Maglic et al. EMBO JOURNAL
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
- (2018) Hanghang Zhang et al. CELL
- Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer
- (2018) Huijun Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
- (2018) Tatsuya Nagano et al. Cells
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
- (2018) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- cAMP response element-binding protein and Yes-associated protein form a feedback loop that promotes neurite outgrowth
- (2017) Lei Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting YAP in malignant pleural mesothelioma
- (2017) Wen-Qian Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
- (2017) Xiaomei Gong et al. Journal of Thoracic Oncology
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
- (2017) Kaidi Li et al. ONCOLOGY REPORTS
- Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
- (2017) Yang Liu et al. OncoTargets and Therapy
- Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors
- (2017) Yoshihiko Taniguchi et al. Oncology Letters
- YAP regulates PD-L1 expression in human NSCLC cells
- (2017) Jinbai Miao et al. Oncotarget
- Hippo pathway in lung development
- (2017) Yuyuan Dai et al. Journal of Thoracic Disease
- RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway
- (2016) Fatéméh Dubois et al. CANCER RESEARCH
- Hippo Wades into Cancer Immunology
- (2016) Thomas Gebhardt et al. DEVELOPMENTAL CELL
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
- (2016) Nan Zhang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Novel therapeutic targets on the horizon for lung cancer
- (2016) Wan-Ling Tan et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
- (2016) Aaron M. Chapman et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
- (2016) S Murakami et al. ONCOGENE
- Melanoma cell adhesion molecule stimulates yes-associated protein transcription by enhancing CREB activity via c-Jun/c-Fos in hepatocellular carcinoma cells
- (2016) YONGXIA QIAO et al. Oncology Letters
- Repression of YAP by NCTD disrupts NSCLC progression
- (2016) Jiwei Guo et al. Oncotarget
- PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
- (2016) Francesco Passiglia et al. Oncotarget
- YAP promotes erlotinib resistance in human non-small cell lung cancer cells
- (2016) Ping-Chih Hsu et al. Oncotarget
- Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
- (2015) C. Zhou et al. ANNALS OF ONCOLOGY
- YAP in MAPK pathway targeted therapy resistance
- (2015) Keith T Flaherty et al. CELL CYCLE
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
- (2015) Y. Kobayashi et al. CLINICAL CANCER RESEARCH
- The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
- (2015) Chunbo He et al. EMBO Molecular Medicine
- YAP/TAZ for cancer therapy: Opportunities and challenges (Review)
- (2015) LIWEN GUO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- 17-AAG suppresses growth and invasion of lung adenocarcinoma cellsviaregulation of the LATS1/YAP pathway
- (2015) Xiang-Yun Ye et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- The Hippo Pathway and YAP/TAZ–TEAD Protein–Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment
- (2015) Matteo Santucci et al. JOURNAL OF MEDICINAL CHEMISTRY
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers
- (2015) Giorgio G. Galli et al. MOLECULAR CELL
- Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
- (2015) Francesca Zanconato et al. NATURE CELL BIOLOGY
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- (2015) Luping Lin et al. NATURE GENETICS
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression
- (2015) C He et al. ONCOGENE
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
- (2015) G. Wang et al. Cancer Discovery
- Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
- (2015) Bin You et al. Oncotarget
- Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
- (2015) Sang Yun Ha et al. Oncotarget
- YAP1 Takes Over when Oncogenic K-Ras Slumbers
- (2014) Florian R. Greten CELL
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
- (2014) Avnish Kapoor et al. CELL
- KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
- (2014) Diane D. Shao et al. CELL
- Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
- (2014) Manuel Valiente et al. CELL
- Pooled analysis of clinical outcome for EGFR TKI-treated patients withEGFRmutation-positive NSCLC
- (2014) Luis Paz-Ares et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer
- (2014) Haruhisa Kitano et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- (2014) Lei Dong et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling
- (2014) David Romano et al. NATURE CELL BIOLOGY
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients
- (2014) SHINSUKE HASHIDA et al. ONCOLOGY REPORTS
- Neuregulin 1-activated ERBB4 as a "dedicated" receptor for the Hippo-YAP pathway
- (2014) M. Sudol Science Signaling
- Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration
- (2014) J. W. Haskins et al. Science Signaling
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
- (2013) C. Zielinski et al. ANNALS OF ONCOLOGY
- CDK1 Phosphorylation of YAP Promotes Mitotic Defects and Cell Motility and Is Essential for Neoplastic Transformation
- (2013) S. Yang et al. CANCER RESEARCH
- Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)–ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration
- (2013) Shuping Yang et al. CELLULAR SIGNALLING
- Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
- (2013) B.V.V.G. Reddy et al. DEVELOPMENTAL CELL
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway
- (2013) Archana Thakur et al. Journal of Translational Medicine
- The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment
- (2013) Randy Johnson et al. NATURE REVIEWS DRUG DISCOVERY
- Enhanced radiosensitivity of NSCLC cells by transducer of erbB2.1 (TOB1) through modulation of the MAPK/ERK pathway
- (2013) KE-KANG SUN et al. ONCOLOGY REPORTS
- Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP
- (2012) Y. Liu-Chittenden et al. GENES & DEVELOPMENT
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14
- (2012) J-M Huang et al. ONCOGENE
- Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma
- (2012) XINYING HUO et al. ONCOLOGY REPORTS
- Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
- (2010) Takeshi Yoshida et al. BIOCHEMICAL PHARMACOLOGY
- Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer
- (2010) Yang Wang et al. CANCER SCIENCE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis
- (2009) Don X. Nguyen et al. CELL
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started